Goldman Sachs Group Inc Voyager Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
A detailed history of Goldman Sachs Group Inc transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 381,709 shares of VYGR stock, worth $2.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
381,709
Previous 180,025
112.03%
Holding current value
$2.9 Million
Previous $1.52 Million
133.9%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding VYGR
# of Institutions
134Shares Held
34.2MCall Options Held
35.3KPut Options Held
63K-
Armistice Capital, LLC New York, NY4.67MShares$35.5 Million0.59% of portfolio
-
Black Rock Inc. New York, NY4.4MShares$33.4 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.92MShares$29.7 Million1.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$24.5 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.29MShares$17.4 Million0.1% of portfolio
About Voyager Therapeutics, Inc.
- Ticker VYGR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,647,600
- Market Cap $293M
- Description
- Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...